Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1FH8R
|
|||
| Drug Name |
ADX-1612
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 1 | [1] | |
| Company |
Aldeyra Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Heat shock protein 90 (HSP90) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Aldeyra Therapeutics | |||
| REF 2 | Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2023 Mar 6;24(5):5014. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.